DLDayu Liu

Dayu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dayu Liu has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Dongguo Lin

    11 shared publications
  • Dongyang Cai

    The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)

    10 shared publications
  • Enqi Huang

    The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)

    10 shared publications
  • Yu Wang

    Department of Laboratory Medicine, the Second Affiliated Hospital, School of Medicine

    10 shared publications
  • Na Yang

    The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)

    7 shared publications
  • Zhenhua Chen

    The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)

    7 shared publications

Latest Publications

  • Fluorescence Encoding-Enabled Multiplexed Droplet Digital Recombinase Polymerase Amplification-CRISPR/Cas12a Assay for Rapid Screening of Lower Respiratory Tract Infection-Associated Bacterial Pathogens

    by Yifan Wang, Enqi Huang, Ziyi Zhang, Xicong Zhu, Ting Zhang, Na Yang, Zhenhua Chen, Dongyang Cai, Dayu Liu

    Digital RPA-CRISPR/Cas12a assays enable accurate nucleic acid quantification; however, their multiplexing capacity is inherently limited by signal confounding arising from the promiscuous trans-cleavage activity of Cas12a effectors. To overcome this limitation, we developed a fluorescence encoding-enabled multiplexed droplet digital RPA-CRISPR/Cas12a (FLEMD-CRISPR) assay that integrates combinatorial fluorescence encoding, deterministic droplet pairing within a calabash-shaped microwell array, and a machine learning-assisted decoding pipeline. In FLEMD-CRISPR, small-volume fluorescence-encoded CRISPR/Cas12a droplets, each assigned a unique spectral signature corresponding to a specific crRNA, are one-to-one paired with large-volume RPA droplets. Following RPA amplification and droplet merging, Cas12a-mediated reporter cleavage occurs only in droplets containing target amplicons. The decoding pipeline then localizes droplets, classifies their colors to assign crRNA identities, and finally detects positive signals, enabling high-throughput, hands-off analysis of the entire droplet array. FLEMD-CRISPR enabled simultaneous quantification of nucleic acid targets from eight major lower respiratory tract infection-associated bacterial pathogens, showing strong linear correlation (R2 = 0.9987–0.9998) and consistent detection efficiency (slopes = 0.9849–1.0198) relative to single-plex digital PCR. The complete workflow, from sample preparation to final readout, can be completed within 2 h. Clinical validation using 30 bronchoalveolar lavage fluid samples showed that the bacterial detection outcomes of FLEMD-CRISPR were highly concordant with standard-of-care culture, achieving 100% (20/20) positive percent agreement and 99.1% (218/220) negative percent agreement. By enabling panel reconfiguration through simple modifications of the droplet encoding library, FLEMD-CRISPR provides a flexible platform for the development of highly multiplexed digital CRISPR assays.

  • Open Access

    Microfluidic Single-Cell Expansion Enabled Comparative Proteomic Analysis to Identify Colon Cancer Stem Cell-Derived Extracellular Vesicle-Specific Biomarkers

    by Xiaogang Wang, Zhuoer Li, Jueming Chen, Weijie Ye, Dongguo Lin, Dayu Liu

    Extracellular vesicles derived from tumor stem cells (TSC-EVs) carry molecular signatures of their parent cells and are promising diagnostic biomarkers, but obtaining sufficient TSC-EVs is hindered by the scarcity of tumor stem cells (TSCs). We developed a microfluidic single-cell expansion approach to selectively propagate colon TSCs and performed comparative proteomic profiling of their EVs. A microfluidic chip with 18,000 microwells and a hydrophilic anti-adhesion coating supported single-cell culture under stemness conditions, generating single-cell-derived tumorspheres at 6.2-12.8% formation efficiency. Each run yielded over 30,000 TSCs, confirmed by elevated CD133, CD44 and LGR5 expression, without surface-marker sorting. Parallel microfluidic cultures produced colon cancer organoids (CCOs) as a differentiated-cell comparator. EVs from TSCs and CCOs were isolated by the EXODUS method and validated by nano-flow cytometry, transmission electron microscopy, and Western blotting. Label-free quantitative proteomics identified 3,615 proteins in TSC-EVs and 4,282 in CCO-EVs, with reproducible TSC-EV profiles that diverged markedly from CCO-EVs. Differentially expressed proteins were enriched in RNA binding, ribosomal biogenesis, and translational pathways. A five-protein TSC-EV biomarker panel (BASP1, ZFTRAF1, LRGUK, HIF1AN, and ELAVL1) was established, with BASP1 showing the highest upregulation (28.47-fold). Because the stem-like and differentiated populations were obtained from the same cell source within one platform, the comparison is internally controlled, and the TSC-EVs enriched proteins can be attributed to the stem-cell state rather than to differences in culture format or cellular background. To our knowledge, this is the first label-free route to sufficient TSC-EV material for comparative proteomics, and it advances EV-based tumor liquid biopsy.

  • Microfluidic single-cell culture represents a versatile approach for tumor stem cell expansion and tumor organoid generation

    by Jueming Chen, Xiaogang Wang, Weijie Ye, Hui Kang, Siyan Xiao, Jiayu Li, Lihui Wang, Dongguo Lin, Dayu Liu

    This study demonstrates the versatility of microfluidic single-cell culture methodologies across diverse types of tumors, facilitating the selective expansion of tumor stem cells and the generation of single-cell-derived tumor organoids.


  • Open Access

    Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer

    by Dongguo Lin, Yanzhang Luo, Jueming Chen, Ziqing Ma, Hui Kang, Xiaogang Wang, Lihui Wang, Dayu Liu

    Tumor heterogeneity drives chemotherapy resistance in cancer, necessitating the development of strategies to target diverse cellular subpopulations. Single-cell-derived tumor organoids (STOs), derived from individual tumor stem cells (TSCs), retain well-defined genomic and phenotypic attributes, making them instrumental in elucidating unique diversification. Here, we developed a microfluidic approach that utilizes STO arrays for personalized drug screening, aimed at overcoming heterogeneity induced drug resistance in colorectal cancer. We utilized a microwell array format microfluidic chip to the generation of a high scale STO array. This array encompasses two key features: (1) STOs in individual microwells are derived from single TSCs, which allows for a high-resolution display of cellular heterogeneity; (2) it exhibits thousands of STOs at predefined locations on the same focal plane, thereby facilitating automated, high-content analyses using imaging data. Utilizing the STO array, we assess the responses of various subpopulations of colorectal cancer to a conventional chemotherapeutic regimen, facilitating the phenotypic identification of resistant STOs. Through the analysis of RNA sequencing data from the resistant STOs, candidate drugs targeting resistance-associated pathways were identified for individual patients. Furthermore, the candidate drugs were validated through STO-array drug testing, demonstrating enhanced clearance effects when combined with the conventional regimen. Our study establishes a scalable, patient-specific drug screening approach that integrates phenotypic and molecular analyses, offering a transformative strategy to overcome heterogeneity-driven drug resistance in colorectal cancer. The microfluidic platform presented herein holds significant potential for advancing precision oncology and personalized therapeutic design.


  • Digital-to-Droplet Microfluidic Platform Powered Digital Isothermal Nucleic Acid Amplification for On-Demand Detection of Post-Transplantation Infection-Causing Viruses

    by Hongting Wen, Enqi Huang, Yuzhang Chen, Ziyi Zhang, Ting Zhang, Na Yang, Zhenhua Chen, Yu Wang, Dongyang Cai, Xianming Liu, et al.

    The etiological diagnosis of severe infectious diseases is complicated by variability in the timing of sample submissions, heterogeneity in detection targets, and stringent requirements for rapid turnaround times, thereby necessitating the development of on-demand detection methodologies. To address these challenges, we introduce an automated digital isothermal nucleic acid amplification (dINA) assay facilitated by a digital-to-droplet (D2D) microfluidic platform. This D2D system permits the continuous introduction and extraction of water-in-oil droplets, enabling the digital microfluidics (DMF) module to alternately interface with multiple droplet microfluidic units. Within this framework, samples or reagents encapsulated in droplets are sequentially delivered to the DMF module, where nucleic acid extraction and subsequent mixing with loop-mediated isothermal amplification (LAMP) reagents are accomplished through a series of precise droplet manipulations. The resultant microliter-scale LAMP reaction droplets are then dispensed into the sample inlets of individual droplet microfluidic modules, where they are partitioned into picoliter-scale droplets for dINA analysis. The principal advantages of this system include (1) the ability to process samples immediately upon receipt, (2) substantial scalability in throughput, and (3) absolute quantification independent of calibration standards. As a proof of concept, this platform was employed to detect viruses responsible for post-transplantation infections, demonstrating a markedly reduced turnaround time for specimens submitted at variable intervals. These findings underscore the potential of this system as an efficient and adaptable diagnostic tool for the on-demand detection of pathogens implicated in severe infectious diseases.


  • Repeated exposure of anticancer agents to tumorspheres in open-surface microwell arrays for modeling chemotherapy-induced dormancy in colorectal cancer

    by Hui Kang, Xiaogang Wang, Weijie Ye, Yanzhang Luo, Jueming Chen, Ziqing Ma, Jiayu Li, Lihui Wang, Dongguo Lin, Dayu Liu

    Tumorspheres in open-surface microwell arrays were repeatedly exposed to an anticancer drug combination to investigate the biological responses and dormancy characteristics of colorectal cancer cells within.

  • Pheno-Molecular Testing Enabled by Multiplex Droplet Digital PCR for Rapid and High-Content Detection of Carbapenem-Resistant Enterobacterales

    by Ziyi Zhang, Dongyang Cai, Ting Zhang, Enqi Huang, Bin Wu, Xiao Yang, Hongting Wen, Yuzhang Chen, Linfen Yu, Xiancheng Li, et al.

    Pheno-molecular testing evaluates bacterial responses to antibiotics via quantitative nucleic acid detection, thus enabling rapid antibiotic susceptibility testing by eliminating the time-consuming isolation culture step. Carbapenems exert their antibacterial effects by disrupting cell wall synthesis, which requires prolonged antibiotic exposure to identify carbapenem-resistant Enterobacterales (CRE) by pheno-molecular testing. To overcome this limitation, we developed a bacterial integrity evaluation-based pheno-molecular testing (Baci-PmT) assay using multiplex droplet digital PCR (mddPCR). This assay features a low-osmolarity culture system supplemented with Meropenem and DNase. Its underlying principle lies in the carbapenem-induced cell wall weakening combined with osmotic pressure-induced outer membrane rupture, resulting in bacterial DNA leakage and subsequent enzymatic degradation. Experimental results show that after 30 min antibiotic exposure, the DNA levels of carbapenem-susceptible Enterobacterales (CSE) were significantly lower than those of CRE. Moreover, the types of carbapenemases were identified by evaluating the synergistic effects of carbapenemase inhibitors and Meropenem on bacterial integrity disruption. Using a color and spatial resolution-based mddPCR system, the Baci-PmT assay enabled the simultaneous identification of CRE-associated bacterial species, CRE phenotypes, and types of carbapenemases. The entire testing process can be completed within 3 to 4.5 h. When analyzing a cohort of 51 clinical samples, the Baci-PmT assay achieved 100% sensitivity and 93.1% specificity in identifying CRE. The concordance rates with conventional assays for determining CRE MIC and the types of carbapenemases were 100% and 87.5%, respectively. The developed Baci-PmT assay can achieve rapid and high-content detection of CRE, offering timely and accurate guidance for clinical interventions in CRE infections.


  • Droplet pairing-merging enabled digital RPA-CRISPR/Cas12a (DIMERIC) assay for rapid and precise quantification of Hepatitis B Virus DNA

    by Dongyang Cai, Yifan Wang, Ziyi Zhang, Enqi Huang, Na Yang, Xiao Yang, Ting Zhang, Hongting Wen, Yu Wang, Zhenhua Chen, et al.


  • Automated Droplet Ejection from a Digital Microfluidics Sample Pretreatment Device Enables Batch-Mode Chemiluminescence Immunoassay

    by Dezhi Huang, Enqi Huang, Dongyang Cai, Zhenhua Chen, Hongting Wen, Yu Wang, Dachuan Ma, Yao Lu, Xianming Liu, Dayu Liu

    Digital microfluidics (DMF) features programmed manipulation of fluids in multiple steps, making it a valuable tool for sample pretreatment. However, the integration of sample pretreatment with its downstream reaction and detection requires transferring droplets from the DMF device to the outside world. To address this issue, the present study developed a modified DMF device that allows automated droplet ejection out of the chip, facilitated by a tailor-designed interface. A double-layered DMF microchip with an oil-filled medium was flipped over, with a liquid infusion port and a liquid expulsion port accommodated on the top working PCB plate and the bottom grounded ITO plate, respectively, to facilitate chip-to-world delivery of droplets. Using chemiluminescent immunoassay (CLIA) as an illustrative application, the sample pretreatment was programmed on the DMF device, and CLIA droplets were ejected from the chip for signal reading. In our workflow, CLIA droplets can be ejected from the DMF device through the chip-to-world interface, freeing up otherwise occupied electrodes for more sample pretreatment and enabling streamlined droplet microreactions and batch-mode operation for bioanalysis. Integrated with these interfacing portals, the DMF system achieved a single-channel throughput of 17 samples per hour, which can be further upscaled for more productive applications by parallelizing the DMF modules. The results of this study demonstrate that the droplet ejection function that is innovated in a DMF sample pretreatment microsystem can significantly improve analytical throughput, providing an approach to establishing an automated but decentralized biochemical sample preparation workstation for large-scale and continuous bioanalysis.